Daratumumab as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy

Haemophilia. 2021 Jul;27(4):e563-e566. doi: 10.1111/hae.14323. Epub 2021 Apr 28.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Humans
  • Monoclonal Gammopathy of Undetermined Significance*
  • Paraproteinemias*
  • von Willebrand Diseases* / complications
  • von Willebrand Diseases* / drug therapy
  • von Willebrand Factor

Substances

  • Antibodies, Monoclonal
  • von Willebrand Factor
  • daratumumab